ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.
about
ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
ProCAID: a phase I clinical tr ...... ion resistant prostate cancer.
@en
type
label
ProCAID: a phase I clinical tr ...... ion resistant prostate cancer.
@en
prefLabel
ProCAID: a phase I clinical tr ...... ion resistant prostate cancer.
@en
P2093
P2860
P1476
ProCAID: a phase I clinical tr ...... ion resistant prostate cancer.
@en
P2093
Alison J Birtle
Gareth Griffiths
Ian Ratcliffe
Karen Martin
Lidia Ksiazek
Mary Ellis
Nichola Downs
Robert J Jones
Stuart Thompson
Vincent Khoo
P2860
P2888
P304
P356
10.1007/S10637-017-0433-4
P577
2017-02-01T00:00:00Z
P6179
1083400198